Dosing Guide
Wegovy Dose Schedule Guide: 0.25 mg to 7.2 mg
Quick Answer: Wegovy treatment begins at 0.25 mg once weekly and increases every four weeks through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose at around week 17. For eligible patients seeking greater weight loss, the dose can be further increased to 7.2 mg after a minimum of four weeks on 2.4 mg. The gradual escalation is designed to minimise side effects and allow the body to adapt to semaglutide. Most patients complete the full escalation and remain on 2.4 mg or 7.2 mg indefinitely as long as treatment is effective and well tolerated.6 stepsin the full Wegovy dose escalation
16 weeksto reach 2.4 mg maintenance under standard schedule
2.4–7.2 mgtarget maintenance dose range
Why Doses Increase Gradually
Why Do Wegovy Doses Increase Gradually?
Wegovy does not begin at its full therapeutic dose. Instead, patients follow a structured dose escalation schedule that spans approximately 16 weeks, progressing through four dose steps before reaching the 2.4 mg maintenance dose. This approach is not arbitrary — it is a clinically designed strategy to balance efficacy with tolerability.
Reducing Gastrointestinal Side Effects
The most common side effects of semaglutide — nausea, vomiting, diarrhoea and abdominal discomfort — are dose-dependent. Starting at 0.25 mg exposes GLP-1 receptors in the gut and brain to semaglutide at a level that is low enough for most patients to tolerate comfortably. Each subsequent dose increase gives the body four weeks to recalibrate before the next step. Clinical data from the STEP 1 trial confirms that this escalation approach significantly reduces early discontinuation rates compared with faster titration protocols.
Allowing Receptor Adaptation
GLP-1 receptors throughout the gastrointestinal tract and central nervous system adapt their sensitivity in response to sustained receptor agonism. The four-week intervals between dose increases are timed to allow this adaptation to occur before further increasing stimulation. This is why patients who attempt to progress through doses faster than the recommended schedule — whether intentionally or due to missed doses — often experience a resurgence of side effects.
Optimising Long-Term Outcomes
Patients who complete the full escalation schedule and reach 2.4 mg tend to achieve greater weight loss than those who remain on lower doses. In the STEP 1 trial, participants who reached and maintained the 2.4 mg dose achieved an average weight loss of approximately 15% of body weight over 68 weeks. Patients who subsequently escalated to 7.2 mg in the STEP UP trial achieved approximately 19–21% weight loss over 72 weeks. The escalation schedule is therefore not only a tolerability strategy — it is integral to maximising clinical outcomes.
Full Schedule
Wegovy Dose Escalation Chart
The table below summarises the complete Wegovy dosing schedule from first injection to maintenance, including the optional 7.2 mg higher dose. The standard schedule is recommended in the MHRA-approved Summary of Product Characteristics (SmPC) and reflects current NICE guidance (TA875).
| Dose | Timeline | Purpose | Side Effects | Key Advice |
|---|---|---|---|---|
| 0.25 mg | Weeks 1–4 | Starting dose | Mild nausea possible | Do not increase early |
| 0.5 mg | Weeks 5–8 | Escalation | Nausea may increase | Monitor GI tolerance |
| 1.0 mg | Weeks 9–12 | Escalation | Peak nausea period | Eat smaller meals |
| 1.7 mg | Weeks 13–16 | Escalation | Nausea easing | Appetite markedly reduced |
| 2.4 mg | Week 17+ | Maintenance | Side effects settle | Long-term dose |
| 7.2 mg | Week 21+ | Higher-dose option | GI symptoms may return briefly | Eligible patients only; single-dose device |
Important: The schedule above represents the standard clinical protocol. Your prescribing clinician or pharmacist may recommend a modified schedule — for example, spending six or eight weeks at each step — based on your individual tolerance, medical history or other clinical factors. Always follow the schedule agreed with your prescribing team.
Dose by Dose
What to Expect at Each Dose Step
0.25 mg — The Starting Dose
The 0.25 mg starting dose is what the prescribing information describes as a tolerability dose rather than a therapeutic dose. At this concentration, semaglutide begins to interact with GLP-1 receptors but does not yet produce the degree of appetite suppression associated with higher doses. Many patients are pleasantly surprised to find that appetite may begin to reduce, food cravings ease, and some early weight loss is common even at this sub-therapeutic dose. Side effects are generally mild — nausea affects some patients but is rarely severe. Do not increase early, even if the dose feels minimal — the four-week interval is pharmacologically necessary, not an optional waiting period. Increasing early substantially raises the risk of severe nausea, vomiting and dehydration.
0.5 mg — First Escalation
At week five, the dose doubles to 0.5 mg. For many patients, this is the first point where they notice a meaningful increase in side effects alongside a more pronounced reduction in appetite. Nausea is more commonly reported at 0.5 mg, and some patients experience their first episode of vomiting at this stage. Most patients manage symptoms within the first one to two weeks of the new dose. Appetite suppression becomes more clinically significant — patients often report a notable reduction in portion sizes and a reduced interest in snacking. Stay well hydrated, and continue the dietary strategies that helped at 0.25 mg: smaller meals, slower eating, avoiding fatty or heavily processed foods.
1.0 mg — Mid-Escalation
The step to 1.0 mg represents the midpoint of the escalation schedule and is frequently associated with the most pronounced side effects of the entire treatment journey. At 1.0 mg, semaglutide reaches a concentration where its effects on both peripheral GLP-1 receptors in the gut and central receptors in the brain are substantially amplified. The transition from 0.5 mg doubles the dose again, and for patients who have been managing symptoms at lower doses, this step can feel like a reset. Nausea peaks at this dose for a significant proportion of patients, and constipation often becomes more noticeable as gastric emptying slows further. It is important to persist through this period — for the majority of patients, symptoms ease considerably within two to three weeks. Appetite suppression at 1.0 mg can be significant enough that some patients struggle to meet daily protein requirements. A daily protein intake of at least 1.2 g per kilogram of body weight is recommended to preserve lean muscle mass.
1.7 mg — Penultimate Step
The 1.7 mg step is the penultimate dose before reaching 2.4 mg maintenance. For many patients, this is where the experience begins to feel more settled — the body has now had twelve weeks to adapt to semaglutide. Nausea may briefly return then ease. Appetite suppression is near its maximum by 1.7 mg, and this is the period of most rapid weight loss for many patients. Maintaining adequate hydration and prioritising nutrient-dense foods is especially important. With one dose step remaining, patients should begin preparing psychologically for long-term maintenance — Wegovy is not a short-term intervention but a chronic disease management tool, and 2.4 mg is intended to be continued indefinitely for eligible patients.
2.4 mg — The Maintenance Dose
The 2.4 mg dose is the licensed maintenance dose for Wegovy in the UK. Having had sixteen or more weeks to adapt, most patients find that nausea is infrequent or absent at 2.4 mg. The degree of appetite suppression stabilises, eating patterns settle into a new normal, and energy levels typically improve. In the STEP 1 trial, patients who reached and sustained 2.4 mg achieved an average reduction in body weight of approximately 14.9% over 68 weeks. Weight loss typically continues gradually throughout the maintenance phase, though the rate slows. Current NICE guidance and MHRA prescribing information both position Wegovy as a long-term treatment for chronic weight management. Stopping is associated with significant weight regain — clinical data demonstrates that patients who discontinue semaglutide regain a substantial proportion of lost weight within 12 months of stopping.
Higher-dose option — Week 21+
7.2 mg — The Higher-Dose Option
Available to eligible patients after a minimum of four weeks on 2.4 mg. It is not a mandatory part of the escalation schedule — patients achieving satisfactory results on 2.4 mg do not need to escalate further. The decision to move to 7.2 mg should be made in consultation with your prescribing clinician, taking into account individual response, tolerability and clinical appropriateness.
The 7.2 mg single-dose device: Unlike doses up to 2.4 mg, which are delivered using the Wegovy FlexTouch® pre-filled pen (four weekly doses per pen), the 7.2 mg dose is administered via a single-dose device. Each carton contains four individual single-dose devices — one per week. The device has an automatic dosing mechanism that activates when pressed against the skin and is discarded after a single use. No priming is required.
STEP UP evidence: In the STEP UP trial, semaglutide 7.2 mg achieved approximately 19–21% average weight loss over 72 weeks. More than 9 in 10 patients achieved at least 5% weight loss; approximately 1 in 3 achieved at least 25%.
Tolerability: Gastrointestinal side effects may temporarily return when stepping up from 2.4 mg to 7.2 mg. For most patients, these ease within two to three weeks. If GI symptoms are significant at 7.2 mg, returning to 2.4 mg is clinically appropriate.
The 7.2 mg single-dose device: Unlike doses up to 2.4 mg, which are delivered using the Wegovy FlexTouch® pre-filled pen (four weekly doses per pen), the 7.2 mg dose is administered via a single-dose device. Each carton contains four individual single-dose devices — one per week. The device has an automatic dosing mechanism that activates when pressed against the skin and is discarded after a single use. No priming is required.
STEP UP evidence: In the STEP UP trial, semaglutide 7.2 mg achieved approximately 19–21% average weight loss over 72 weeks. More than 9 in 10 patients achieved at least 5% weight loss; approximately 1 in 3 achieved at least 25%.
Tolerability: Gastrointestinal side effects may temporarily return when stepping up from 2.4 mg to 7.2 mg. For most patients, these ease within two to three weeks. If GI symptoms are significant at 7.2 mg, returning to 2.4 mg is clinically appropriate.
Missed Doses
What Happens If You Miss a Dose?
Missing an occasional dose of Wegovy is not a clinical emergency, but it does require a clear response to avoid side effects on resumption and maintain treatment continuity.
Why Missed Doses Matter
Semaglutide has a half-life of approximately one week, meaning blood concentrations fall meaningfully between injections. Multiple missed doses can result in a significant drop in semaglutide levels, and resuming at the same dose can cause a recurrence of nausea and other side effects. Consistency is one of the most important factors in maintaining both tolerability and weight loss outcomes.
| Scenario | What to Do |
|---|---|
| Missed dose — 5 days or fewer have passed | Take the missed dose as soon as you remember, then resume your usual weekly injection day. |
| Missed dose — more than 5 days have passed | Skip the missed dose entirely. Take your next dose on your usual scheduled day. Do not double up. |
| Missed multiple doses (1–2 weeks) | Resume on your normal schedule. You may experience a temporary return of side effects. Contact your prescribing pharmacist for guidance. |
| Extended break (4+ weeks) | Do not restart at your previous dose. Contact your prescribing clinician — a dose reduction and re-escalation may be required. |
| Missed dose during escalation phase | Follow the rules above. Do not advance to the next dose step after a missed dose — complete a full four weeks at your current dose first. |
Practical Tip: Set a recurring weekly reminder on your phone for your injection day. Consistency in day and time reduces the risk of missed doses and helps establish a reliable routine for long-term treatment.
Lower Doses
Can You Stay on a Lower Dose of Wegovy?
Patients sometimes ask whether it is possible to remain on a lower dose — such as 1.0 mg or 1.7 mg — rather than completing the escalation to 2.4 mg. This is a clinically valid question, and the answer depends on individual circumstances.
When a Lower Dose May Be Appropriate
In a small number of patients, side effects at higher doses are severe enough to justify remaining at a lower dose for a longer period or indefinitely. This decision should always be made in consultation with your prescribing clinician rather than unilaterally. A lower dose will generally produce less appetite suppression and slower weight loss than 2.4 mg, but for some patients the tolerability trade-off is worth it.
The Clinical Evidence for 2.4 mg
The STEP trial programme consistently demonstrated that 2.4 mg outperforms lower doses on all primary efficacy endpoints including percentage weight loss, reduction in waist circumference and improvement in metabolic markers. For patients who can tolerate it, 2.4 mg offers the greatest clinical benefit. Remaining on a lower dose is a pragmatic compromise rather than an optimal strategy.
Slower Escalation as an Alternative
For patients struggling to tolerate the standard four-week escalation intervals, a slower escalation schedule — spending six or eight weeks at each dose step rather than four — is a clinically recognised alternative. This extends the total time to reach maintenance but significantly improves tolerability for many patients. Your prescribing pharmacist can advise on whether a modified schedule is appropriate for you.
| Dose Option | Considerations |
|---|---|
| Remain at 1.0 mg | Tolerable for most patients; significantly lower efficacy than 2.4 mg. Not the standard recommendation. |
| Remain at 1.7 mg | A reasonable interim option for patients experiencing severe side effects at 2.4 mg. Clinical review recommended. |
| Slower escalation to 2.4 mg | The preferred alternative to staying on a sub-maintenance dose. Extends timeline but achieves full maintenance dose. |
| 2.4 mg standard maintenance | The licensed and recommended maintenance dose. Optimum efficacy in clinical trials. |
| 7.2 mg (optional escalation) | For eligible patients after ≥4 weeks on 2.4 mg. STEP UP trial: ~19–21% weight loss at 72 weeks. Uses the single-dose device. |
Key Questions
Key Questions Answered
What is the Wegovy dose schedule?
The Wegovy dose schedule begins at 0.25 mg once weekly for four weeks, then increases to 0.5 mg, 1.0 mg and 1.7 mg at four-week intervals before reaching the maintenance dose of 2.4 mg at approximately week 17. The total escalation period is 16 weeks. For eligible patients, the dose can be further increased to 7.2 mg after a minimum of four weeks on 2.4 mg. Doses up to 2.4 mg are administered using the FlexTouch® pre-filled pen; 7.2 mg uses a single-dose device.
How quickly do Wegovy doses increase?
Wegovy doses increase every four weeks under the standard escalation schedule. This interval is clinically determined — it allows the body sufficient time to adapt to each dose level before the next increase. Some patients follow a slower schedule of six to eight weeks per dose step if tolerability is a concern. Increasing doses faster than recommended is not advised and significantly raises the risk of severe gastrointestinal side effects.
Can I stay on a lower Wegovy dose?
Yes, in some circumstances — but it is not the first-line recommendation. The 2.4 mg maintenance dose is the licensed standard because it consistently produces the best clinical outcomes in terms of weight loss and metabolic improvement. For patients seeking additional weight loss, escalation to 7.2 mg is an option after a minimum of four weeks on 2.4 mg. However, patients who experience intolerable side effects at higher doses may remain at 1.0 mg or 1.7 mg with their prescribing clinician's agreement. A slower escalation schedule is often a better option than remaining on a sub-maintenance dose long-term, as it allows most patients to eventually reach 2.4 mg with improved tolerability.
FAQs
Frequently Asked Questions: Wegovy Dose Schedule
Wegovy starts at 0.25 mg once weekly for four weeks, then increases to 0.5 mg, 1.0 mg and 1.7 mg at four-week intervals before reaching the 2.4 mg maintenance dose at approximately week 17. For eligible patients, the dose can be further increased to 7.2 mg after a minimum of four weeks on 2.4 mg. The 7.2 mg dose uses a single-dose device rather than the FlexTouch® pen.
The starting dose of Wegovy is 0.25 mg once weekly. This is a tolerability dose rather than a full therapeutic dose, designed to allow the body to adjust to semaglutide before the dose is increased. It is taken for the first four weeks of treatment.
Wegovy is injected once weekly, on the same day each week. The day of the week can be chosen by the patient and can be changed if needed, provided the gap between doses is at least five days.
The standard maintenance dose of Wegovy is 2.4 mg once weekly. For eligible patients, the dose can be increased to 7.2 mg once weekly after a minimum of four weeks on 2.4 mg. The 7.2 mg dose is administered via a single-dose device rather than the FlexTouch® pen used for lower doses.
No. The four-week intervals between dose increases are clinically necessary to allow your body to adapt and to minimise side effects. Attempting to escalate faster than recommended carries a significant risk of severe nausea, vomiting and dehydration.
If fewer than five days have passed since your scheduled injection, take the missed dose as soon as you remember. If more than five days have passed, skip it and resume on your usual injection day the following week. Never take two doses in one week. A single missed dose is unlikely to cause significant side effects on resumption.
Under the standard four-week escalation schedule, patients reach the 2.4 mg maintenance dose at the start of week 17. Patients who then escalate to 7.2 mg can do so after a minimum of four further weeks (week 21 at the earliest). Patients following a slower escalation schedule will take longer.
Unlike doses up to 2.4 mg, which use the Wegovy FlexTouch® pre-filled pen (four weekly doses per pen), the 7.2 mg dose is administered via a single-dose device. Each carton contains four individual single-dose devices — one per week. The device has an automatic mechanism that activates when pressed against the skin, and is discarded after a single use. No priming is required.
Wegovy is intended as a long-term treatment for chronic weight management. Current guidance supports long-term continuation as long as the patient continues to benefit and the treatment remains clinically appropriate. Stopping Wegovy is associated with significant weight regain — the STEP 4 trial showed approximately two-thirds of lost weight regained within 12 months of discontinuation.
Yes. If side effects at any dose step are intolerable, your prescribing clinician may recommend pausing at your current dose for a further four weeks before attempting to escalate again, or reducing back to the previous dose temporarily. This is a recognised approach in clinical practice.
Short breaks from Wegovy (up to four weeks) can generally be managed by resuming on your usual schedule. For longer breaks or those involving significant changes in health status, contact your prescribing clinician before restarting — a dose reduction may be appropriate.
Wegovy injections are generally well tolerated. The needle is very fine and the injection volumes are small. Most patients report minimal discomfort. Injection site reactions such as mild redness or bruising are common but transient. Rotating injection sites between the abdomen, thigh and upper arm helps reduce local irritation.
Yes, the injection day can be changed as long as the new schedule maintains at least five days between doses. For example, if your usual day is Monday and you wish to change to Thursday, you can do so as long as your last injection was at least five days ago.
Standard Wegovy prescribing in the UK does not mandate specific blood tests during dose escalation, though monitoring requirements may vary by prescribing pathway. Happy Pharmacy's clinical team provides guidance on monitoring throughout your treatment journey.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Check Your Eligibility →
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. | Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;S2213–8587(25):00226–8. | Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy (STEP 3). JAMA. 2021;325(14):1403–1413. | MHRA. Semaglutide (Wegovy) prescribing information. 2023. gov.uk/mhra | NICE TA875. Semaglutide for managing overweight and obesity. March 2023. | Novo Nordisk. Wegovy (semaglutide 2.4 mg and 7.2 mg) Summary of Product Characteristics. 2023/2025. | GPhC. Standards for registered pharmacies. 2023. gphc.org.uk | Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not a substitute for individualised clinical assessment.